多西他赛节拍化疗治疗老年晚期非小细胞肺癌疗效观察

目的探讨多西他赛单药节拍化疗一线治疗老年晚期非小细胞肺癌（NSCLC）的疗效及安全性。方法将20例老年晚期NSCLC患者作为节拍组（多西它赛25mg／m^2静脉滴注1h，第1、8、15天给药，每28天为1个周期），另20例为对照组（多西他赛75mg／m^2静脉滴注1h，第1天给药，每3周重复）。比较2组化疗2周期后的近期疗效、生活质量及毒性反应。结果节拍组近期疗效的有效率、临床受益率虽高于对照组，但差异无统计学意义（P〉0．05）；节拍组患者化疗后生活质量改善情况优于对照组（P〈0．01），药物毒性反应较对照组轻（P〈0．05或P〈0．01）。结论多西他赛单药节拍化疗治疗老年晚期NSCLC患者安全有效，优于传统治疗方法。

Clinical observation of metronomic docetaxel chemotherapy to treat advanced non -small cell lung cancer in elderly patients

Objective To explore the efficacy and safety of metronomic docetaxel monotherapy to treat advanced non - small cell lung cancer （NSCLC） in elderly patients. Methods Twenty elderly patients with advanced NSCLC were included into a treatment group who received metronomic docetaeel chemotherapy （through one hour of intravenous infusion with 25 mg/m^2 docetacel on Days 1,8 and 15, with a cycle length of 28 days）. Meanwhile, another twenty patients were enrolled into a control group and given traditional docetaxel chemotherapy （ through one hour of intravenous infusion with 75 mg/m： docetacel on Day 1, which was repeated every three weeks）. After two cycles of treatment, the short - term efficacy, quality of life and toxic reactions were compared between both groups. Results The treatment group presented a higher effective rate and better clinical benefit response （CBR） than the control group, in spite of no statistical difference （ P 〉 0.05 ）. After metronomic therapy, the patients reported better quality of life （ P 〈 0.01 ） and less toxic reactions （P 〈 0.05 or P 〈 0.01 ） than those in the control group. Conclusion Metronomic doeetaxel chemotherapy is superior to the traditional regime with respect to its effectiveness and safely when applied to elderly patients with NSCLC.